Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L, Döhner K.

Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.

2.

Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.

Kresinsky A, Schnöder TM, Jacobsen ID, Rauner M, Hofbauer LC, Ast V, König R, Hoffmann B, Svensson CM, Figge MT, Hilger I, Heidel FH, Böhmer FD, Müller JP.

Oncogene. 2019 Jun;38(24):4773-4787. doi: 10.1038/s41388-019-0757-y. Epub 2019 Feb 28.

PMID:
30820040
3.

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells.

Dash BP, Schnöder TM, Kathner C, Mohr J, Weinert S, Herzog C, Godavarthy PS, Zanetti C, Perner F, Braun-Dullaeus R, Hartleben B, Huber TB, Walz G, Naumann M, Ellis S, Vasioukhin V, Kähne T, Krause DS, Heidel FH.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1933-1944. doi: 10.1007/s00432-018-2724-3. Epub 2018 Aug 6.

PMID:
30083817
4.

Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia.

Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP.

Haematologica. 2018 Nov;103(11):e505-e509. doi: 10.3324/haematol.2017.185306. Epub 2018 Jun 7. No abstract available.

5.

Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells.

Ranjan S, Goihl A, Kohli S, Gadi I, Pierau M, Shahzad K, Gupta D, Bock F, Wang H, Shaikh H, Kähne T, Reinhold D, Bank U, Zenclussen AC, Niemz J, Schnöder TM, Brunner-Weinzierl M, Fischer T, Kalinski T, Schraven B, Luft T, Huehn J, Naumann M, Heidel FH, Isermann B.

Nat Commun. 2017 Aug 21;8(1):311. doi: 10.1038/s41467-017-00169-4.

6.

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation.

Tsitsipatis D, Jayavelu AK, Müller JP, Bauer R, Schmidt-Arras D, Mahboobi S, Schnöder TM, Heidel F, Böhmer FD.

Oncotarget. 2017 Apr 18;8(16):26613-26624. doi: 10.18632/oncotarget.15772.

7.

Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.

Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH.

J Cancer Res Clin Oncol. 2017 May;143(5):807-820. doi: 10.1007/s00432-017-2354-1. Epub 2017 Feb 23.

PMID:
28233092
8.

Gain of function in Jak2V617F-positive T-cells.

Nishanth G, Wolleschak D, Fahldieck C, Fischer T, Mullally A, Perner F, Schnöder TM, Just S, Heidel FH, Schlüter D.

Leukemia. 2017 Apr;31(4):1000-1003. doi: 10.1038/leu.2017.6. Epub 2017 Jan 11. No abstract available.

PMID:
28074070
9.

Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML.

Perner F, Schnöder TM, Fischer T, Heidel FH.

Anticancer Res. 2016 Dec;36(12):6249-6258.

PMID:
27919943
10.

Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo.

Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH.

Haematologica. 2016 Mar;101(3):e81-5. doi: 10.3324/haematol.2015.136754. Epub 2015 Nov 20. No abstract available.

11.

Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.

Arreba-Tutusaus P, Mack TS, Bullinger L, Schnöder TM, Polanetzki A, Weinert S, Ballaschk A, Wang Z, Deshpande AJ, Armstrong SA, Döhner K, Fischer T, Heidel FH.

Leukemia. 2016 May;30(5):1220-1225. doi: 10.1038/leu.2015.292. Epub 2015 Oct 21. No abstract available.

12.

Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function.

Perner F, Schnöder TM, Ranjan S, Wolleschak D, Ebert C, Pils MC, Frey S, Polanetzki A, Fahldieck C, Schönborn U, Schraven B, Isermann B, Fischer T, Heidel FH.

Leukemia. 2016 Apr;30(4):991-5. doi: 10.1038/leu.2015.218. Epub 2015 Aug 5. No abstract available.

PMID:
26242463
13.

Epo-induced erythroid maturation is dependent on Plcγ1 signaling.

Schnöder TM, Arreba-Tutusaus P, Griehl I, Bullinger L, Buschbeck M, Lane SW, Döhner K, Plass C, Lipka DB, Heidel FH, Fischer T.

Cell Death Differ. 2015 Jun;22(6):974-85. doi: 10.1038/cdd.2014.186. Epub 2014 Nov 14.

14.

Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function.

Wolleschak D, Mack TS, Perner F, Frey S, Schnöder TM, Wagner MC, Höding C, Pils MC, Parkner A, Kliche S, Schraven B, Hebel K, Brunner-Weinzierl M, Ranjan S, Isermann B, Lipka DB, Fischer T, Heidel FH.

Haematologica. 2014 Jun;99(6):e90-3. doi: 10.3324/haematol.2014.104331. Epub 2014 Mar 14. No abstract available.

Supplemental Content

Loading ...
Support Center